Infliximab: a new treatment for rheumatoid arthritis

Infliximab, a chimeric mouse human monoclonal antibody, is an anti-TNF treatment for rheumatoid arthritis. In the past there was a sizeable group of people who had exhausted disease-modifying antirheumatic drugs (DMARDs) and were left largely untreated. This has been revolutionized by treatments such as infliximab which have been shown to be effective for patients in whom standard DMARDs have failed.